FDA Commissioner Marty Makary resigned from his position on May 12, 2026. The departure was noted on Wait Wait... Don't Tell Me! as Peter Sagal referenced the agency head stepping down during a quiz segment.
Controversy surrounding Marty Makary had been building prior to his exit. On Today, Explained, the host noted the friction with activist groups: "Um, they were angry at FDA administrator Marty Makary 'cause he approved a generic." This follows a pattern of scrutiny where the FDA is forced to balance intense political pressure with its mandate, with hosts observing that the agency was "extremely cautious in approving mifepristone."
Beyond leadership changes, the FDA remains the central bottleneck for pharmaceutical innovation. On 99% Invisible, Sean Cole argued that the agency is the "main factor driving this ceaseless crusade for nominal innovation." Meanwhile, the agency continues to face enforcement challenges, such as its ongoing investigation into illegal substances like those on Radiolab, where Latif Nasser recounted how individuals involved in unauthorized treatments "fled the US because they were being investigated by the FDA."
Looking ahead, the FDA faces a busy transition period. With a flurry of recent approvals for cancer and asthma therapies, plus a new reassessment of food additives like BHT and ADA, the agency is signaling a shift toward more aggressive post-market oversight. Expect continued debate over whether these regulatory actions are protective consumer measures or, as noted on Criminal, a foundational evolution of the government's role in "protecting American consumers."
